EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers

Shuang Chen iD, Shuyue Ye iD, Gang Huang iD, Zhichen Sun, Qiang Feng, Maggie Wang, Raymundo Pantoja iD, Baran D Sumer, Jinming Gao iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2409570122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Shuang Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 7539…. Hauptthemen laut MEDLINE: Membrane Proteins, Cancer Vaccines, Nanoparticles, Papillomavirus Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas (CPRIT), Foundation for the National Institutes of Health (FNIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, therapeutic cancer vaccines have been extensively investigated, aiming to boost cancer-specific T cells crucial for antitumor activity. The effectiveness of these vaccines is often limited by insufficient immune activation and suboptimal antigen delivery. Stimulator of interferon genes (STING) is an important immune signaling protein that activates host defense genes against infection and cancer. Clinical evaluation of small-molecule STING agonists has shown tepid antitumor responses with immune-related toxicities, particularly when they are administered systemically. To overcome these limitations, we report a stimuli-responsive STING nanovaccine for treating human papillomavirus (HPV)-induced cancers. The nanovaccine consists of di-amidobenzimidazoles (diABZI) conjugated to a STING-activating polymer, PSC7A, through an azobenzene linker as an adjuvant, and HPV16 E7 protein as an antigen. The nanovaccine is responsive to acidic pH and NAD(P)H quinone oxidoreductase 1 (NQO1), which enhances antitumor immunity with reduced systemic toxicity. Upon intravenous injection, the STING nanovaccine (25 to 30 nm in diameter) achieved efficient codelivery of E7 protein and STING agonists to the myeloid cell populations in the secondary lymphoid organs and tumors. Interestingly, PSC7A uptake induces NQO1 expression in dendritic cells and macrophages for accelerated diABZI cleavage and STING activation. This results in efficient production of E7-specific CD8 + T cells and robust antitumor response in late-stage TC-1 and metastatic MLM3 tumor models. This study illustrates a systemic STING nanovaccine design that allowed not only tumor regression but also markedly reduced systemic toxicity for innate activation to achieve cancer-specific T cell immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsCancer VaccinesNanoparticlesPapillomavirus InfectionsNeoplasmsAnimalsMiceHumansFemalePapillomavirus E7 ProteinsMice, Inbred C57BLCD8-Positive T-LymphocytesCell Line, TumorNanovaccinesSTING Protein

Stichwörter der Autor:innen

HPV-induced cancerSTING signalingT cell therapynanoparticle vaccinestimuli-responsive nanoparticles

Substanzen

Membrane ProteinsCancer VaccinesPapillomavirus E7 ProteinsNanovaccinesSting1 protein, mouseSTING Proteinoncogene protein E7, Human papillomavirus type 16STING1 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390.
  • Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390.
  • Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390.
  • Department of Otolaryngology, University of Texas Southwestern Medical Center, Dallas, TX 75390.
  • Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390.

ORCID-Profile: Shuang Chen, Shuyue Ye, Gang Huang, Raymundo Pantoja, Jinming Gao

Förderung

  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas (CPRIT)
  • Foundation for the National Institutes of Health (FNIH)

Zitieren

APA

Chen, S., Ye, S., Huang, G., Sun, Z., Feng, Q., Wang, M., Pantoja, R., Sumer, B. D., & Gao, J. (2025). Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2409570122

Vancouver

Chen S, Ye S, Huang G, Sun Z, Feng Q, Wang M, et al. Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2409570122

BibTeX
@article{Chen2025,
  author = {Chen, Shuang and Ye, Shuyue and Huang, Gang and Sun, Zhichen and Feng, Qiang and Wang, Maggie and Pantoja, Raymundo and Sumer, Baran D and Gao, Jinming},
  title = {Stimuli-responsive STING nanovaccine for systemic therapy of HPV-induced cancers},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2409570122}
}
Kostenlos starten →